InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

- Current share price for NUZ : $0.068

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$53 Neurizon to present Q3 FY2025 Results 6 May 2025 12:48PM $0.135 $0.068 fallen by 49.63%
$53 Last Patient Successfully Completes Treatment in OLE Study 5 May 2025 9:23AM $0.140 $0.068 fallen by 51.43%
$53 Appendix 4C & Quarterly Update 28 Apr 2025 9:11AM $0.120 $0.068 fallen by 43.33%
$53 Notice of Quarterly Shareholder Update Webinar 24 Apr 2025 9:28AM $0.125 $0.068 fallen by 45.60%
$53 Appointment of Chief Financial Officer 22 Apr 2025 9:28AM $0.120 $0.068 fallen by 43.33%
$53 Leadership team strengthened with strategic appointments 17 Apr 2025 9:22AM $0.100 $0.068 fallen by 32%
$53 NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells 4 Apr 2025 12:07PM $0.115 $0.068 fallen by 40.87%
$53 NUZ-001 Shows Positive Results in Human 3D Brain Model 1 Apr 2025 9:03AM $0.130 $0.068 fallen by 47.69%
$53 NUZ-001 shows promising respiratory outcome 24 Mar 2025 9:47AM $0.110 $0.068 fallen by 38.18%
$53 Neurizon Commences Initiatives to Lift Clinical Hold 17 Mar 2025 9:22AM $0.110 $0.068 fallen by 38.18%
$53 Appendix 4D - Half-year Financial Report - 31 December 2024 17 Feb 2025 2:28PM $0.155 $0.068 fallen by 56.13%
$53 Neurizon to Present Latest Results and Key Updates 17 Feb 2025 9:27AM $0.130 $0.068 fallen by 47.69%
$53 FDA Guidance on NUZ-001 IND Application 17 Feb 2025 9:14AM $0.130 $0.068 fallen by 47.69%
$53 Notice of Company Update Webinar 11 Feb 2025 2:29PM $0.138 $0.068 fallen by 50.55%
$53 Change of Director's Interest Notices x3 7 Feb 2025 9:58AM $0.140 $0.068 fallen by 51.43%
$53 US Patent granted for NUZ-001 5 Feb 2025 9:18AM $0.125 $0.068 fallen by 45.60%
$53 Notification regarding unquoted securities - NUZ 31 Jan 2025 4:46PM $0.125 $0.068 fallen by 45.60%
$53 Appendix 4C & Quarterly Update 29 Jan 2025 9:14AM $0.125 $0.068 fallen by 45.60%
$53 Neurizon updates on NUZ-001 IND Application 17 Jan 2025 9:59AM $0.170 $0.068 fallen by 60%
$53 Change of Share Registry 16 Jan 2025 8:19AM $0.160 $0.068 fallen by 57.50%
$53 Section 708A Cleansing Statement 27 Dec 2024 5:07PM $0.170 $0.068 fallen by 60%
$53 Application for quotation of securities - NUZ 27 Dec 2024 5:00PM $0.170 $0.068 fallen by 60%
$53 Neurizon Files IND Application to Support HEALEY ALS Trial 18 Dec 2024 9:13AM $0.175 $0.068 fallen by 61.14%
$53 Neurizon Granted OMPD for NUZ-001 in Europe 17 Dec 2024 8:52AM $0.165 $0.068 fallen by 58.79%
$53 Positive 8-month Interim Data from OLE Study 16 Dec 2024 9:34AM $0.180 $0.068 fallen by 62.22%

126 - 150 of 172 results

Page 6 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.